Gyrus in the news
Essential Pharma acquires Renaissance Pharma Ltd with its Clinical Stage Immunotherapy for the Treatment of High-Risk Neuroblastoma
Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas, announces that it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd…